Cronos Group Stock Today
| CRON Stock | USD 2.21 0.10 4.74% |
Performance0 of 100
| Odds Of DistressLess than 33
|
Cronos is selling at 2.21 as of the 12th of October 2024; that is 4.74 percent increase since the beginning of the trading day. The stock's open price was 2.11. Cronos has about a 33 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Cronos Group are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of September 2024 and ending today, the 12th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of July 2016 | Category Healthcare | Classification Health Care |
It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada. The company has 382.28 M outstanding shares of which 4.98 M shares are currently shorted by private and institutional investors with about 5.63 trading days to cover. More on Cronos Group
Moving together with Cronos Stock
Moving against Cronos Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cronos Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Michael JD | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cannabis (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Cronin Group Plc | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Cannabis, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCronos can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cronos' financial leverage. It provides some insight into what part of Cronos' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cronos Group (CRON) is traded on NASDAQ Exchange in USA. It is located in 111 Peter Street, Toronto, ON, Canada, M5V 2H1 and employs 356 people. Cronos is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 844.84 M. Cronos Group conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 382.28 M outstanding shares of which 4.98 M shares are currently shorted by private and institutional investors with about 5.63 trading days to cover.
Cronos Group currently holds about 944.89 M in cash with (41.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.5, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cronos Probability Of Bankruptcy
Ownership AllocationCronos holds a total of 382.28 Million outstanding shares. Cronos Group retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cronos Ownership Details
Cronos Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-06-30 | 550.2 K | |
| Penserra Capital Management, Llc | 2024-06-30 | 544.5 K | |
| Hillsdale Investment Management Inc. | 2024-06-30 | 478.4 K | |
| Renaissance Technologies Corp | 2024-06-30 | 464.9 K | |
| Kerrisdale Advisers, Llc | 2024-06-30 | 458.2 K | |
| Janney Montgomery Scott Llc | 2024-06-30 | 440.9 K | |
| Cannell Capital Llc | 2024-06-30 | 434.4 K | |
| Qube Research & Technologies | 2024-06-30 | 432.2 K | |
| Swiss National Bank | 2024-06-30 | 415.4 K | |
| Chescapmanager Llc | 2024-06-30 | 8 M | |
| Vanguard Group Inc | 2024-06-30 | 7.2 M |
Cronos Historical Income Statement
Cronos Stock Against Markets
Cronos Corporate Management
| James III | Controller VP | Profile | |
| Arye Weigensberg | Senior Development | Profile | |
| Shayne Laidlaw | Director Strategy | Profile | |
| Terry Doucet | General Secretary | Profile | |
| Kevin Gifford | VP Fin | Profile | |
| James Holm | Chief Officer | Profile | |
| Anna Shlimak | Senior Strategy | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cronos Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cronos. If investors know Cronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cronos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.144 | Earnings Share (0.16) | Revenue Per Share 0.267 | Quarterly Revenue Growth 0.46 | Return On Assets (0.04) |
The market value of Cronos Group is measured differently than its book value, which is the value of Cronos that is recorded on the company's balance sheet. Investors also form their own opinion of Cronos' value that differs from its market value or its book value, called intrinsic value, which is Cronos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cronos' market value can be influenced by many factors that don't directly affect Cronos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cronos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cronos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cronos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.